The list of medical technologies approved for innovation funding (NUB) in Germany in 2018

On the 30th  of January, 2018, the Institute for the Hospital Remuneration System (InEK) has published the List of the requests for innovation funding (NUB), submitted until the 31st of October, 2017. Out of 705 requests, 171 (24%) received the positive status 1, which means that the evaluated procedure or medical device meets the NUB criteria and allows the hospitals to negotiate with the sickness funds for the innovation funding for these technologies.

The full list of 72 technologies, obtained the status 1, provided below:

• Insertion of coated (covered) stents with bioactive surface for peripheral vessels;
• Implantation of an intracardiac pulse generator;
• Covered endoprosthesis with bioactive surface for dialysis shunt revision;
• Endovascular implantation of an internal AV shunt by means of magnetically guided high-frequency energy;
• Ascites treatment by means of a fully implantable pump;
• Hemodynamically effective implant for the endovascular treatment of intracranial aneurysms and brain-supplying neck vessels;
• Percutaneous mitral valve anulorrhaphy with clasp;
• Intra-aneurysmal hemodynamically effective implant for endovascular treatment of intracranial aneurysms;
• External stabilization framework for anastomosis of an AV shunt in the context of shunt surgery;
• Gastric pacemaker implantation;
• Endo-barrier for the treatment of obese type 2 diabetics;
• Ultra-soft, removable micro-coils for the therapy of intracranial vascular malformations and aneurysms;
• Transmission of virus-specific donor immune cells after allogeneic stem cell transplantation;
• Endovascular mitral valve annuloplasty with annuloplasty tape;
• Wire mesh for flow reduction in the coronary sinus;
• Endovascular implantation of an extracorporeal centrifugal pump for circulatory system support;
• Transapical mitral valve reconstruction by implantation of neochordae (PTFE);
• Focal photodynamic therapy with Padeliporfin for the treatment of localized prostate cancer;
• Hypoglossal nerve stimulation system for the treatment of obstructive sleep apnea syndrome (OSAS);
• Catheter-based implant for the treatment of left ventricular cardiac motility disorders;
• Radionuclide therapy with lutetium 177-labeled prostate-specific membrane antigen (PSMA) in prostate cancer;
• Lung volume reduction by means of bronchoscopic application of polymer foam;
• Intra-aortic catheter with paracorporeal membrane pump for circulatory support of the left ventricle;
• Temporomandibular joint replacement (total replacement);
• Minimally invasive LV reconstruction with a myocardial anchoring system;
• Intra-aortal balloon occlusion with extracorporeal circulation;
• Transapical implantation of an extracorporeal centrifugal pump for circulatory system support;
• Selective intravascular radionuclide therapy (SIRT) with holmium 166-labeled microspheres for radioembolization;
• Therapy of scoliosis by means of magnetically controlled rods;
• Implant for direct acoustic stimulation of the cochlea (DACI);
• Insertion of coated (covered) stents with bioactive surface for peripheral and other vessels;
• Apicoaortal valve-carrying conduit;
• Insertion of coated (covered) stents with bioactive surface for intraabdominal, cranial or peripheral vessels;
• Implantation of growing heart valves;
• Epiretinal retinal prosthesis;
• Intracavitary radiotherapy with iodine 125;
• Cardiac Resynchronization Therapy with Wireless Left Ventricular Endocardial Pacing;
• Extracorporeal neurostimulation system for the peripheral nervous system;
• Endovascular mitral valve annuloplasty with seam anchoring;
• Insertion of coated (covered) stents with bioactive surface for visceral and supraaortal vessels;
• Fetoscopic drainage therapy;
• Radioimmunotherapy with anti-CD19, anti-CD45 and anti-CD66 antibodies;
• Pulmonary arterial banding, telemetrically adjustable;
• Endo-Exo-Prostheses;
• Subretinal active implant;
• Therapy of scoliosis by means of a growing screw-rod-system;
• Fetoscopic tracheal balloon lock in case of diaphragmatic hernia and premature tuberosity;
• Keratoprosthesis, biologically coated;
• Lock of umbilical cord and intrafetal vessels by percutaneous ultrasound-controlled radiofrequency ablation or fetoscopic laser ablation;
• Auditory brainstem implant;
• Fetoscopic opening of narrowed semilunar valves and the foramen ovale;
• Fetoscopic therapy of fetal supraventricular tachycardia and laryngeal or trachea occlusion;
• Fetoscopic patch closure at Spina bifida aperta;
• Allogeneic hepatocyte transplantation;
• Artificial larynx after total laryngectomy;
• Radionuclide therapy with lutetium-177 bisphosphonate in bone metastases of the prostate carcinoma;
• Uterine shield closure after fetoscopic interventions;
• Spine growth modulation technique;
• Lutetium-177- or yttrium-90-pentixafor therapy;
• Growth endoprosthesis;
• Acoustic neuroma operation with simultaneous cochlear implantation;
• Auditory midbrain implant;
• Autologous matrix-induced hepatocyte transplantation;
• Treatment of fatal epidermolysis bullosa junctionalis (M. Herlitz) by transplantation of haploidentical bone marrow and skin of the same donor;
• Childhood treatment of the bladder / prostate / rectum / perineal region rhabdomyosarcoma with organ-preserving surgery and interstitial HDR brachytherapy;
• Combined renal and stem cell transplantation (living donation);
• Continuous amnion infusion by subcutaneous implanted port system;
• Radionuclide therapy with iodine-131-azetidinylamide in metastatic adrenal carcinoma;
• Radionuclide therapy with iodine-131-metomidate;
• Uterus transplantation;
• Complete face transplantation;
• Epiphysial growth-directing stapling of spine with shape memory alloy (SMA) staples.

See full details in German here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.